论文部分内容阅读
目的：评价１７９９７（２０ｍｇ·Ｌ－１）滴眼治疗实验性单纯疱疹性角膜炎（ｈｅｒｐｅｓｓｉｍｐｌｅｘｋｅｒａｔｉｔｉｓ，ＨＳＫ）的疗效及滴眼剂的刺激性。方法：建立兔眼ＨＳＫ动物模型，以１ｇ·Ｌ－１无环鸟苷滴眼剂作为阳性对照，以０．１５ｍｏｌ·Ｌ－１生理盐水作为阴性对照，采用裂隙灯观察角膜病变情况并评分、病毒分离检测及透射电镜观察评价１７９９７疗效。采用Ｄｒａｉｚｅ眼刺激实验评价药物毒性。结果：１７９９７（２０ｍｇ·Ｌ－１）可有效地治疗ＨＳＫ，减轻角膜病变程度，缩短平均治愈时间，疗效与无环鸟苷相似。１７９９７滴眼剂（２０ｍｇ·Ｌ－１）及其赋形剂的Ｄｒａｉｚｅ评分结果表明，１７９９７滴眼剂无眼刺激性。结论：广谱抗病毒药１７９９７治疗实验性单纯疱疹性角膜炎获得了与无环鸟苷相似的疗效，且无临床毒性
Objective: To evaluate the efficacy of 17997 (20 mg · L-1) instillation in the treatment of experimental herpes simplex keratitis (HSK) and eye irritation. Methods: Rabbit eye HSK animal model was established. The rabbits were given 1g · L -1 acyclovir eye drops as the positive control and 0.15mol·L -1 saline as the negative control. The slit lamp was used to observe the corneal lesions and score. Virus isolation and transmission electron microscopy were used to evaluate the efficacy of 17997. Draize eye irritation test to evaluate drug toxicity. Results: 17997 (20mg · L-1) can effectively treat HSK, reduce the degree of corneal lesions and shorten the average healing time, with a similar efficacy and acyclovir. The Draize score of 17997 Eye Drops (20 mg · L-1) and its excipients showed no eye irritation of 17997 Eye Drops. Conclusion: A broad-spectrum antiviral drug 17997 for treatment of experimental herpes simplex keratitis achieved similar efficacy as acyclovir with no clinical toxicity